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Abstract 
Context Hirata’s Disease (HD) is a rare autoimmune cause of hypoglycemia. Patients suffering from this 
condition have a genetic predisposition, determined by HLA DR4, with some differences in the worldwide 
population. In Caucasians HLA DRB1*0403 is the most frequent susceptibility background on which some 
drugs play as triggers. 
Case Description We reported the case of a woman with several hypoglycemic episodes, characterized by high 
insulin and c-peptide levels. Biochemical and morphological exams excluded a neuroendocrine tumor. Hirata’s 
Disease was diagnosed according to insulin autoantibodies (IAA) positivity and patient’s history, particularly 
about drugs taken. The HLA analysis revealed DRB1*0415 allele. 
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Conclusions We found a potential new predisposing factor for HD, HLA DRB1*0415 allele, never described 
before as genetic background to Insulin Autoimmune Syndrome in Caucasians. 
Keywords: hypoglycemia, alpha lipoic acid, insulin autoantibodies, Insulin Autoimmune Syndrome. 
Introduction 
Insulin Autoimmune Syndrome (IAS), also known as Hirata’s Disease (HD), is a rare cause of hypoglycemia, 
most frequent in Japan where it represents the third cause of hypoglycemia [1], with up to 380 reported cases [2]. 
This autoimmune syndrome is characterized by spontaneous hypoglycemic episodes with insulin autoantibodies 
(IAA) positivity in patients who have never received exogenous insulin treatment. The specific mechanism by 
which IAA lead to hypoglycemic episodes is not clear. The main hypothesis is that insulin produced by 
pancreatic β-cells after food intake is bound by IAA, creating IAA-insulin complexes which are a circulating 
insulin reserve. During the fasting period, when circulating insulin levels are reduced, the insulin release from 
the IAA could be responsible of the hypoglycemic episodes [3]. Another hypothesis is that IAA could induce the 
production of anti-idiotype antibodies which might bind insulin receptors and be functionally similar to 
circulating insulin. 
Like other autoimmune disorders, IAS is characterized by a genetic predisposition associated with the Human 
Leukocyte Antigen (HLA) DR4. In Japanese population, particularly, there is a strong association between IAS 
and HLA DRB1*0406, and less likely with DRB1*0403 and DRB1*0407. The higher prevalence in Japan could 
be explained by the different distribution of HLA DR4 alleles around the world. Indeed, HLA-DRB1*0406 is 
prevalent in Eastern Asian population while HLA DRB1*0403 is mainly expressed in Caucasians [4]. 
On this genetic background the use of some drugs can play an important role. Various medications are reported 
to lead to IAS, and all of them are sulfhydryl compounds able to reduce the disulfide bridges between the two 
insulin chains, increasing the insulin immunogenicity [2]. 
Case report 
A 76-year-old woman with type 2 diabetes (T2DM) was admitted to the Inpatient Endocrinology Clinic on 
February 2018 because of recurrent hypoglycemic episodes. She had never used insulin to treat her T2DM. 
Metformin was prescribed at the diagnosis, but she spontaneously suspended it when the first hypoglycemic 
episode occurred. 
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During the hospitalization, several symptomatic and spontaneous hypoglycemic episodes occurred, all 
characterized by high levels of insulin (47.1-50.4-46.5-53.7-43.3 µUI/ml – normal values <30.0) and c-peptide 
(17.8-17-16-19.1-14.7 ng/ml – reference range 1.1-3.5). Cortisol, ACTH and GH values were in the normal 
range. The factitious use of sulfonylureas was excluded. 
In order to exclude an insulin-secreting tumor, Neuron Specific Enolase (NSE) was measured but was in the 
normal range (14.4 ng/ml). Cromogranin A was elevated (1511 ng/ml) during proton pump inhibitor treatment 
but decreased to 101.4 ng/ml after removing the pharmacological interference. As morphological study of the 
pancreas a contrast CT scan, an echoendoscopy and an abdomen MRI scan were performed, but no lesion 
suspected of neuroendocrine tumor was identified. A 68-Ga-DOTATOC PET excluded the presence of 
somatostatin receptor-positive lesions. 
For the persistence of symptomatic hypoglycemic episodes during the hospitalization, diazoxide was prescribed 
and continued after discharge from hospital, obtaining a good control of symptoms and blood glucose values. 
In the next few months, blood glucose levels progressively increased, so the diazoxide dose was reduced 
accordingly. In June 2018 the patient was admitted again to the Inpatient Endocrinology Clinic where diazoxide 
was suspended. At the end of a prolonged fasting test asymptomatic low blood glucose values (53-56-50 mg/dl) 
were observed but associated with normal insulin (15.1-14.1-16.1 µUI/ml) and c-peptide (0.9-0.9-0.9 ng/ml) 
levels, resulting in a normal response.  
Suspecting IAS, IAA were measured and resulted elevated (45.5 AU/ml; normal values <0.4). The hypothesis of 
IAS was sustained by the medication history because she had taken a dietary supplement containing alpha lipoic 
acid (ALA) to treat her diabetic neuropathy for a few weeks before the first hospitalization.  
Glycated haemoglobin (HbA1c) was 82 mmol/mol, suggesting poorly-controlled diabetes and spontaneous 
remission of hypoglicemia. 
After a few months, the patient was asymptomatic without diazoxide. HbA1c was 51 mmol/mol in the absence 
of pharmacological interference, and IAA gradually decreased (35.8-16.6 AU/ml) (Table 1). Further on, blood 
glucose profile showed values in upper normal limits without any treatment. 
The HLA analysis revealed HLA DRB1*0415 allele, never described before in association with IAS, to our 
knowledge. 
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Discussion 
IAS is a rare autoimmune condition, especially in Europe, but potentially under- or misdiagnosed. The 
differential diagnosis of symptomatic hypoglycemia may be hard, including various causes such as sepsis, 
hepatic, renal, or cardiac failure, drugs, and less frequently insulinoma, and insulin like growth factor-II 
secreting tumors [5]. In this context the IAS diagnosis could be more difficult because of clinical features 
simulating insulinoma. There are some case reports of IAS being misdiagnosed as cases of insulinoma and 
therefore undergoing pancreas surgery, not only in the past, but even more recently [6]. Based on its role in the 
differential diagnosis, the IAA measurement is now recommended by the clinical practice guideline [5,7]. 
In our case the diagnostic hypothesis was raised by high insulin levels associated with normal pancreas 
morphology, progressive elevation of blood glucose levels during diazoxide, and finally spontaneous remission. 
The hypothesis was confirmed assessing IAA, which turned positive. After diagnosis, it would be important to 
identify the responsible for the IAA development in order to avoid further exposure. In fact, because of their 
trigger role, drugs must be carefully investigated. Drug history, including dietary supplement, could be crucial 
for suspecting IAS. A lot of sulfhydryl compounds are commonly used to treat various illnesses [2]. 
The first case of IAS associated with ALA assumption was reported in Japan in 2003 [2]. Between 2004 and 
2007, 17 cases of IAS after ALA were described in Japan; 12 of them were analyzed for HLA, reporting 
DRB1*0406 and DRB1*0403 in 10 and 2 patients, respectively [2]. The first Italian IAS after ALA was 
described in 2011, with HLA DRB1*0406 [8]. ALA is widely used as nutritional supplement for its antioxidant 
properties and as adjuvant treatment for diabetic neuropathy. ALA assumption could be very hard to investigate 
because many patients like ours do not consider it as a pharmacological product but a natural dietary supplement, 
so it won’t be mentioned in the medication history. 
The different prevalence of IAS around the world, despite the widespread use of the same sulfhydryl 
compounds, could have a genetic base, secondary to the distribution of HLA DR4 alleles in Japanese vs. 
Caucasian population [4]. The Italian cases reported until January 2019 mostly expressed HLA DRB1*0403 
(9/15), and less frequently HLA DRB1*0406 (2/15), and HLA DRB1*0407 (1/15). In the remaining 3 patients 
HLA assessment was not performed [9,10,11]. Going into details, out of the 15 Italian patients with IAS, 10 were 
described after taking ALA; HLA DRB1*0403 and DRB1*0406 were identified in 8 and 2 of them, respectively. 
To our knowledge, this is the first case characterized by HLA DRB1*0415, suggesting that other HLA DR4 
alleles could lead to IAS. (Table 2). 
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Conclusion 
In conclusion, IAS should be included in the differential diagnosis of hypoglycemia according to the clinical 
practice guideline, in order to avoid under- or misdiagnosis. 
Although HLA analysis cannot be reasonably performed in every patient taking sulfhydryl compounds, it would 
be interesting to evaluate the genetic predisposition in advance, at least for research purposes. 
The increasing number of ALA-induced hypoglycemic episodes calls for caution in prescribing these compounds 
and assessing self-medications practices when hypoglycemic episodes are not explained otherwise. 
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Time Plasma glucose (mg/dl) HbA1c (mmol/mol) Insulin (µUI/ml) C-peptide (ng/ml) IAA (AU/ml) Cromogranin A (ng/ml) NSE (ng/ml) 
First Admission 21 44 47,1 17,8 NP 1511 14,4 
During Diazoxide 225 82 NP NP NP NP NP 
Second Admission 133 80 NP NP 45,5 101,4 NP 
Fasting testa 50 NP 16,1 0,9 NP NP NP 
After hospital discharge  
(1 month) 124 75 34,9 2,7 35,8 NP NP 
After hospital discharge 
 (5 months) 127 51 35,6 2,4 16,5 184 NP 
 
Table 1. Biochemestry laboratory values of the reported case (NP= Not Performed) 
a Reported are the lowest plasma glucose during the fasting test and the corresponding levels of Insulin and C-peptide 
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Patient Age Sex Trigger Plasma glucose (mg/dl) Insulin (µUI/ml) C-peptide (ng/ml) IAA HLA Therapy 
1 Pediatric M ND 34 ND ND ND ND NS 
2 58 F ND 20 426 ND Positive ND Plasmapheresis/Prednisone 
3 70 F ALA 24 57 11,9 Positive HLA-DRB1*0406 Prednisone/Diazoxide 
4 40 F ND 47 43 4,6 Positive ND Plasmapheresis 
5 75 M ALA 29 4930 4,1 Positive HLA-DRB1*0406 Prednisone 
6 77 F ALA 36 8000 7,1 Positive HLA-DRB1*0403 Prednisone 
7 53 M ALA 26 52900 6,8 Positive HLA-DRB1*0403 Prednisone 
8 40 F ALA 35 533 5,1 Positive HLA-DRB1*0403 Fractionated meals 
9 70 F ALA 45 3200 4,8 Positive HLA-DRB1*0403 Prednisone 
10 56 M ALA 40 2200 6,5 Positive HLA-DRB1*0403 Prednisone 
11 78 F ND 44 1000 3,1 Positive HLA-DRB1*0407 Prednisone 
12 54 M ND 52 600 2,9 Positive HLA-DRB1*0403 Fractionated meals 
13 56 F ALA 21 8500 18,4 Positive HLA-DRB1*0403 Prednisone 
14 66 F ALA 24 197 3,4 Positive HLA-DRB1*0403 Prednisone 
15 82 F ALA 34 >1500 4,2 Positive HLA-DRB1*0403 Prednisone 
Present case 76 F ALA 21 47,1 17,8 Positive HLA-DRB1*0415 Diazoxide 
 
Table 2. Features of the Italian cases of IAS reported so far. (ND= Not Determined, NS= Not Specified, ALA= Alpha Lipoic Acid). 
 
 
